← Back to Search

Cannabinoid

Loaded CANNAXR for Solar Elastosis (CNXR-001D Trial)

N/A
Waitlist Available
Research Sponsored by MINO Labs, LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 weeks
Awards & highlights

CNXR-001D Trial Summary

This trial found that UV light can cause mutations in DNA, leading to skin aging, like wrinkles.

Eligible Conditions
  • Solar Elastosis

CNXR-001D Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Title: Double-Blind Study to measure and compare the Mean Percent Reduction UVA induced premutagenic and photoaging markers 8-oxo-dG and the common deletion in 20 subjects treated with CANNAXR and Vehicle and exposed to 3X their individual MED-UVA

CNXR-001D Trial Design

1Treatment groups
Experimental Treatment
Group I: Loaded CANNAXRExperimental Treatment2 Interventions
In a double-blinded fashion, 250 mg CANNAXR cream and 250 mg VEHICLE cream will be randomized for application to a delineated 50 cm2 area of either the left or right, hip/buttocks skin twice daily for 2 weeks. In a double-blinded fashion, 250 mg CANNAXR cream and 250 mg VEHICLE cream will be randomized for application to a delineated 50 cm2 area of either the left or right, hip/buttocks skin twice daily for 2 weeks.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
In a double-blinded fashion, 250 mg CANNAXR cream
2023
N/A
~20
Topical VEHICLE cream
2023
N/A
~20

Find a Location

Who is running the clinical trial?

MINO Labs, LLCLead Sponsor

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Double-Blind Study Determining the Efficacy of CannaXR in Decreasing UVA Premutagenic and Photoaging Markers
2023. "Double-Blind Study Determining the Efficacy of CannaXR in Decreasing UVA Premutagenic and Photoaging Markers". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05279495.
~9 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top